ArticleFrontiers in oncology2025

Case Report: Ensartinib as a first-line treatment for SMARCA4-deficient and EML4-ALK non-small cell lung cancer.

Yanqing Pan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.